Tiny study on bone markers in myeloma ends early
NCT ID NCT04111809
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study aimed to track four bone-related substances in the blood and urine of multiple myeloma patients treated with intravenous bisphosphonates (bone-strengthening drugs). Researchers wanted to see how these markers changed over 12 months. Only 3 patients were enrolled before the study was stopped, so no meaningful conclusions could be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Necker Hospital, Adult haematology department
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.